NeuroMetrix (NASDAQ:NURO) Coverage Initiated at StockNews.com

Analysts at StockNews.com began coverage on shares of NeuroMetrix (NASDAQ:NURO) in a note issued to investors on Sunday. The firm set a “sell” rating on the medical device company’s stock.

NeuroMetrix Stock Up 1.3 %

NASDAQ:NURO opened at $3.95 on Friday. The company has a market cap of $8.07 million, a P/E ratio of -0.86 and a beta of 2.18. NeuroMetrix has a twelve month low of $2.66 and a twelve month high of $4.73. The business has a 50 day moving average price of $4.06 and a two-hundred day moving average price of $3.84.

NeuroMetrix (NASDAQ:NURO) last announced its earnings results on Tuesday, November 5th. The medical device company reported ($0.75) EPS for the quarter. NeuroMetrix had a negative return on equity of 42.56% and a negative net margin of 203.71%. The business had revenue of $0.59 million for the quarter. During the same period last year, the firm earned ($1.66) EPS.

NeuroMetrix Company Profile

NeuroMetrix, Inc, a commercial stage neurotechnology company, engages in designing, building, and marketing medical devices that stimulate and analyze nerve response for diagnostic and therapeutic purposes in the United States, Europe, Japan, and China. Its marketed products include DPNCheck, a nerve conduction test that is used to evaluate peripheral neuropathies, such as diabetic peripheral neuropathy; Quell, a wearable device for symptomatic relief and management of chronic pain; and ADVANCE system offers services to device and provide disposable electrodes to a customer base of hand surgeons and manufacturers for industrial health use.